Adherex Technologies (NASDAQ:FENC) Stock Rating Upgraded by Zacks Research

Adherex Technologies (NASDAQ:FENC – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday, Zacks reports.

Other analysts have also recently issued research reports about the company. Wedbush raised their target price on Adherex Technologies from $13.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. B. Riley Financial reissued a “buy” rating and set a $18.00 target price (up from $16.00) on shares of Adherex Technologies in a research report on Wednesday, August 12th. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Adherex Technologies in a research note on Wednesday, September 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adherex Technologies in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Check Out Our Latest Stock Analysis on FENC

Adherex Technologies Trading Up 6.6%

Shares of NASDAQ FENC traded up $0.72 during midday trading on Thursday, reaching $11.62. The company’s stock had a trading volume of 461,196 shares, compared to its average volume of 155,058. The company has a market cap of $409.20 million, a price-to-earnings ratio of 1,162.00 and a beta of 1.29. Adherex Technologies has a one year low of $5.65 and a one year high of $13.25. The company has a 50 day moving average price of $10.64 and a 200 day moving average price of $9.36.

Adherex Technologies (NASDAQ:FENC – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. The company had revenue of $19.61 million during the quarter, compared to the consensus estimate of $18.87 million. Adherex Technologies had a return on equity of 9.58% and a net margin of 2.52%. Research analysts anticipate that Adherex Technologies will post 0.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Robert Andrade sold 75,000 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $11.78, for a total value of $883,500.00. Following the sale, the chief financial officer owned 217,675 shares in the company, valued at approximately $2,564,211.50. The trade was a 25.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider owned 9,519 shares in the company, valued at approximately $115,941.42. This trade represents a 55.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 10.73% of the stock is currently owned by company insiders.

Adherex Technologies Company Profile

(Get Free Report)

Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.

Recommended Stories

Analyst Recommendations for Adherex Technologies (NASDAQ:FENC)

Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.